Top 5 AJMC® Articles of April 2019

Hi, I’m Jaime Rosenberg for The American Journal of Managed Care. Here are the top 5 articles from the month of April.

Number 5: After a year in development, the Community Oncology Alliance is set to file its alternative to CMS’ Oncology Care Model with the Physician-Focused Payment Model Technical Advisory Committee.

Number 4: Results from a recent study indicate that a revolutionary treatment may have the potential to slow, stop, or even reverse the progression of Parkinson disease.

Number 3: Oncologists and hematologists welcomed a clarification from the CDC about the use of opioid pain relief for patients with cancer, past cancer, or sickle cell disease.

Number 2: Based on results of the REDUCE-IT study, Amarin has submitted a supplemental new drug application for an expanded label for its drug Vascepa, which was also included in a mid-year update to the American Diabetes Association’s 2019 Standards of Medical Care in Diabetes.

Number 1: Results from the CREDENCE trial demonstrated that type 2 diabetes drug canagliflozin cut the risk of renal failure or death by 30% in patients with type 2 diabetes and chronic kidney disease.

To read all of these articles and more, visit AJMC.com.